1. Home
  2. EVF vs IFRX Comparison

EVF vs IFRX Comparison

Compare EVF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Senior Income Trust

EVF

Eaton Vance Senior Income Trust

HOLD

Current Price

$5.31

Market Cap

95.9M

Sector

Finance

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.03

Market Cap

81.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVF
IFRX
Founded
1998
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.9M
81.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
EVF
IFRX
Price
$5.31
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
93.3K
647.2K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
10.68%
N/A
EPS Growth
N/A
N/A
EPS
0.94
N/A
Revenue
N/A
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
$6.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.20
$0.71
52 Week High
$6.84
$2.77

Technical Indicators

Market Signals
Indicator
EVF
IFRX
Relative Strength Index (RSI) 45.04 45.22
Support Level $5.25 $1.00
Resistance Level $5.38 $1.10
Average True Range (ATR) 0.04 0.08
MACD 0.00 -0.00
Stochastic Oscillator 36.60 15.22

Price Performance

Historical Comparison
EVF
IFRX

About EVF Eaton Vance Senior Income Trust

Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: